JPWO2020017587A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020017587A5 JPWO2020017587A5 JP2020531363A JP2020531363A JPWO2020017587A5 JP WO2020017587 A5 JPWO2020017587 A5 JP WO2020017587A5 JP 2020531363 A JP2020531363 A JP 2020531363A JP 2020531363 A JP2020531363 A JP 2020531363A JP WO2020017587 A5 JPWO2020017587 A5 JP WO2020017587A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- alkyl
- alkoxy
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000005843 halogen group Chemical group 0.000 claims 101
- 125000000217 alkyl group Chemical group 0.000 claims 93
- 125000003545 alkoxy group Chemical group 0.000 claims 85
- 229920006395 saturated elastomer Polymers 0.000 claims 64
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 63
- 125000002837 carbocyclic group Chemical group 0.000 claims 41
- 125000000623 heterocyclic group Chemical group 0.000 claims 41
- 229910052799 carbon Inorganic materials 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims 21
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 14
- -1 6-methylpyridin-3-yl Chemical group 0.000 claims 13
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 12
- 150000001721 carbon Chemical group 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 7
- 229910052731 fluorine Inorganic materials 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 claims 6
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 206010015037 epilepsy Diseases 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 230000000069 prophylactic effect Effects 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 3
- 208000015114 central nervous system disease Diseases 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000002091 Febrile Seizures Diseases 0.000 claims 2
- 208000003078 Generalized Epilepsy Diseases 0.000 claims 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 2
- 229940035678 anti-parkinson drug Drugs 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 229940126585 therapeutic drug Drugs 0.000 claims 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- WTCWHVGXMDKSLM-UHFFFAOYSA-N 2-(6-oxo-3-spiro[2.5]oct-6-en-6-ylpyridazin-1-yl)-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide Chemical compound O=C1C=CC(=NN1CC(=O)NC1=CC=2N(C=C1)N=CN=2)C1=CCC2(CC2)CC1 WTCWHVGXMDKSLM-UHFFFAOYSA-N 0.000 claims 1
- JNPQNXCZVIFNMZ-UHFFFAOYSA-N 2-[2-oxo-2-(4-pyridazin-4-yl-2,3-dihydroindol-1-yl)ethyl]-6-spiro[2.5]oct-6-en-6-ylpyridazin-3-one Chemical compound O=C(CN1N=C(C=CC1=O)C1=CCC2(CC2)CC1)N1CCC2=C(C=CC=C12)C1=CN=NC=C1 JNPQNXCZVIFNMZ-UHFFFAOYSA-N 0.000 claims 1
- ADICAMULCAGLDQ-UHFFFAOYSA-N 2-[3-(4,4-dimethylcyclohexen-1-yl)-6-oxopyridazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide Chemical compound CC1(CC=C(CC1)C1=NN(C(C=C1)=O)CC(=O)NC=1C=CC=2N(C=1)N=CN=2)C ADICAMULCAGLDQ-UHFFFAOYSA-N 0.000 claims 1
- ZYRYTCOACGPHEV-UHFFFAOYSA-N 2-[3-(4,4-dimethylcyclohexen-1-yl)-6-oxopyridazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide Chemical compound CC1(CC=C(CC1)C1=NN(C(C=C1)=O)CC(=O)NC1=CC=2N(C=C1)N=CN=2)C ZYRYTCOACGPHEV-UHFFFAOYSA-N 0.000 claims 1
- GPDYSOJPVLEOCW-UHFFFAOYSA-N 2-[3-(6-azaspiro[3.4]octan-6-yl)-6-oxopyridazin-1-yl]-N-quinazolin-7-ylacetamide Chemical compound C1CCC11CN(CC1)C1=NN(C(C=C1)=O)CC(=O)NC1=CC=C2C=NC=NC2=C1 GPDYSOJPVLEOCW-UHFFFAOYSA-N 0.000 claims 1
- MCQIGXDZBMRMHH-ZDUSSCGKSA-N 2-[3-[(4R)-4-methylcyclohexen-1-yl]-6-oxopyridazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide Chemical compound C[C@H]1CC=C(CC1)C1=NN(C(C=C1)=O)CC(=O)NC=1C=CC=2N(C=1)N=CN=2 MCQIGXDZBMRMHH-ZDUSSCGKSA-N 0.000 claims 1
- JUXVHCWFAGDRPD-ZDUSSCGKSA-N 2-[3-[(4R)-4-methylcyclohexen-1-yl]-6-oxopyridazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide Chemical compound C[C@H]1CC=C(CC1)C1=NN(C(C=C1)=O)CC(=O)NC1=CC=2N(C=C1)N=CN=2 JUXVHCWFAGDRPD-ZDUSSCGKSA-N 0.000 claims 1
- MCQIGXDZBMRMHH-CYBMUJFWSA-N 2-[3-[(4S)-4-methylcyclohexen-1-yl]-6-oxopyridazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-6-yl)acetamide Chemical compound C[C@@H]1CC=C(CC1)C1=NN(C(C=C1)=O)CC(=O)NC=1C=CC=2N(C=1)N=CN=2 MCQIGXDZBMRMHH-CYBMUJFWSA-N 0.000 claims 1
- JUXVHCWFAGDRPD-CYBMUJFWSA-N 2-[3-[(4S)-4-methylcyclohexen-1-yl]-6-oxopyridazin-1-yl]-N-([1,2,4]triazolo[1,5-a]pyridin-7-yl)acetamide Chemical compound C[C@@H]1CC=C(CC1)C1=NN(C(C=C1)=O)CC(=O)NC1=CC=2N(C=C1)N=CN=2 JUXVHCWFAGDRPD-CYBMUJFWSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000001573 Cataplexy Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010021750 Infantile Spasms Diseases 0.000 claims 1
- 208000035899 Infantile spasms syndrome Diseases 0.000 claims 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 claims 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 1
- KYGDWRZSRCNCFH-UHFFFAOYSA-N N-(1,3-benzoxazol-5-yl)-2-[3-(4-methylcyclohexen-1-yl)-6-oxopyridazin-1-yl]acetamide Chemical compound O1C=NC2=C1C=CC(=C2)NC(CN1N=C(C=CC1=O)C1=CCC(CC1)C)=O KYGDWRZSRCNCFH-UHFFFAOYSA-N 0.000 claims 1
- OEJLJABPNGZFIR-UHFFFAOYSA-N N-(1,3-benzoxazol-5-yl)-2-[3-(4-methylpiperidin-1-yl)-6-oxopyridazin-1-yl]acetamide Chemical compound O1C=NC2=C1C=CC(=C2)NC(CN1N=C(C=CC1=O)N1CCC(CC1)C)=O OEJLJABPNGZFIR-UHFFFAOYSA-N 0.000 claims 1
- SRFRUCXPJOBWHA-UHFFFAOYSA-N N-(4-cyanophenyl)-2-[3-(4-methylpiperidin-1-yl)-6-oxopyridazin-1-yl]acetamide Chemical compound C(#N)C1=CC=C(C=C1)NC(CN1N=C(C=CC1=O)N1CCC(CC1)C)=O SRFRUCXPJOBWHA-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 201000006791 West syndrome Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- XMSZANIMCDLNKA-UHFFFAOYSA-N methyl hypofluorite Chemical group COF XMSZANIMCDLNKA-UHFFFAOYSA-N 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 230000002151 myoclonic effect Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018136152 | 2018-07-19 | ||
| JP2018136152 | 2018-07-19 | ||
| PCT/JP2019/028256 WO2020017587A1 (ja) | 2018-07-19 | 2019-07-18 | ピリダジノン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020017587A1 JPWO2020017587A1 (ja) | 2021-08-05 |
| JPWO2020017587A5 true JPWO2020017587A5 (https=) | 2022-07-26 |
| JP7476100B2 JP7476100B2 (ja) | 2024-04-30 |
Family
ID=69163916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531363A Active JP7476100B2 (ja) | 2018-07-19 | 2019-07-18 | ピリダジノン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220347175A1 (https=) |
| EP (1) | EP3828174A4 (https=) |
| JP (1) | JP7476100B2 (https=) |
| CN (1) | CN112672997A (https=) |
| CA (1) | CA3105681A1 (https=) |
| WO (1) | WO2020017587A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3877052B1 (en) | 2018-11-06 | 2023-08-16 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| ES2958954T3 (es) | 2018-11-06 | 2024-02-16 | Edgewise Therapeutics Inc | Compuestos de piridazinona y usos de los mismos |
| WO2020097258A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| WO2021141041A1 (ja) * | 2020-01-07 | 2021-07-15 | 大日本住友製薬株式会社 | タウオパチーの治療剤 |
| WO2021149767A1 (ja) * | 2020-01-22 | 2021-07-29 | 大日本住友製薬株式会社 | ヘテロ環誘導体 |
| JP2023523418A (ja) * | 2020-04-23 | 2023-06-05 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｌｒｐ３の阻害剤としての三環式化合物 |
| KR20230035049A (ko) * | 2020-07-02 | 2023-03-10 | 데날리 테라퓨틱스 인크. | 화합물, 조성물 및 방법 |
| CN116964052A (zh) * | 2021-03-04 | 2023-10-27 | 詹森药业有限公司 | 调节nlrp3的4-氨基-6-氧代-哒嗪衍生物 |
| MX2023010310A (es) * | 2021-03-04 | 2023-09-12 | Janssen Pharmaceutica Nv | Derivados de 4-alcoxi-6-oxo-piridazina que modulan nlrp3. |
| US12054486B2 (en) | 2021-09-24 | 2024-08-06 | Xenon Pharmaceuticals Inc. | Pyridine derivatives and their use as sodium channel activators |
| CN115650968B (zh) * | 2022-12-27 | 2023-03-21 | 英矽智能科技(上海)有限公司 | 作为cdk选择性抑制剂的新型哒嗪酮化合物 |
| GB2640329A (en) * | 2024-04-09 | 2025-10-15 | Imperial College Innovations Ltd | Hedgehog acyltransferase inhibitors |
| WO2025215121A1 (en) * | 2024-04-09 | 2025-10-16 | Imperial College Innovations Limited | Hedgehog acyltransferase inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100770327B1 (ko) * | 2000-09-18 | 2007-10-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피리다지논 및 트리아지논 화합물류 및 그들의 의약 용도 |
| GB0216224D0 (en) | 2002-07-12 | 2002-08-21 | Glaxo Group Ltd | Compounds |
| FR2889847B1 (fr) | 2005-08-18 | 2007-10-05 | Sanofi Aventis Sa | Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique. |
| EP2145891A1 (en) * | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
| US20140073651A1 (en) | 2011-02-22 | 2014-03-13 | Actelion Pharmaceuticals Ltd. | Benzamide derivatives as p2x7 receptor antagonists |
| CN102964340B (zh) * | 2012-12-12 | 2015-10-07 | 中国药科大学 | 一类治疗阿尔茨海默病的选择性多巴胺d1受体激动剂 |
| EP2968323A4 (en) * | 2013-03-13 | 2016-12-14 | Flatley Discovery Lab | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| EP3419621A4 (en) * | 2016-02-26 | 2019-10-30 | The Johns Hopkins University | PHARMACOLOGICAL MODULATORS OF NAV1.1 VOLTAGE-CONTROLLED SODIUM CHANNELS ASSOCIATED WITH MECHANICAL PAIN |
| WO2017210685A1 (en) * | 2016-06-03 | 2017-12-07 | An2H Discovery Limited | Pyradazinone derivatives and the compositions and methods of treatment regarding the same |
| CA3041675A1 (en) * | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
| WO2018081378A1 (en) * | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
-
2019
- 2019-07-18 EP EP19838697.1A patent/EP3828174A4/en not_active Withdrawn
- 2019-07-18 CN CN201980061100.6A patent/CN112672997A/zh active Pending
- 2019-07-18 US US17/260,831 patent/US20220347175A1/en not_active Abandoned
- 2019-07-18 CA CA3105681A patent/CA3105681A1/en active Pending
- 2019-07-18 WO PCT/JP2019/028256 patent/WO2020017587A1/ja not_active Ceased
- 2019-07-18 JP JP2020531363A patent/JP7476100B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020017587A5 (https=) | ||
| JP2020033357A5 (https=) | ||
| RU2336275C2 (ru) | Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция | |
| JP7476100B2 (ja) | ピリダジノン誘導体 | |
| RU2017122364A (ru) | N-((гет)арилметил)-гетероарил-карбоксамидные соединения в качестве ингибиторов плазменного калликреина | |
| JP2009536620A5 (https=) | ||
| EA031655B1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| CA2651363A1 (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| SI2961736T1 (en) | Histone demethylase inhibitors | |
| JP2011520832A5 (https=) | ||
| RU2009103300A (ru) | Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии | |
| JP2021528446A5 (https=) | ||
| JP2018522861A5 (https=) | ||
| CA2570197A1 (en) | Nk1 antagonists | |
| JP2021500332A5 (https=) | ||
| JP2007502275A5 (https=) | ||
| JP2017528515A5 (https=) | ||
| JP2015524483A5 (https=) | ||
| JP2022550353A5 (https=) | ||
| JP2019537581A5 (https=) | ||
| RU2014144951A (ru) | Новое 1-замещенное производное индазола | |
| JP2020503295A5 (https=) | ||
| RU2013125338A (ru) | Производные триазола в качестве лигандов рецепторов гамк | |
| JP2022549601A5 (https=) |